| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics
|
Nikanjam, M.
|
|
|
30 |
10 |
p. 1675
|
article
|
| 2 |
Breaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?
|
Glutsch, V.
|
|
|
30 |
10 |
p. 1667-1668
|
article
|
| 3 |
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|
Cardoso, F.
|
|
|
30 |
10 |
p. 1674
|
article
|
| 4 |
Early-drug development in the era of immuno-oncology: are we ready to face the challenges?
|
Ochoa de Olza, M.O.
|
|
|
30 |
10 |
p. 1670
|
article
|
| 5 |
Editorial Board
|
|
|
|
30 |
10 |
p. ii-iii
|
article
|
| 6 |
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
|
Burstein, H.J.
|
|
|
30 |
10 |
p. 1541-1557
|
article
|
| 7 |
Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer
|
Siravegna, G.
|
|
|
30 |
10 |
p. 1671
|
article
|
| 8 |
Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting
|
Amant, F.
|
|
|
30 |
10 |
p. 1601-1612
|
article
|
| 9 |
Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
|
Stjepanovic, N.
|
|
|
30 |
10 |
p. 1558-1571
|
article
|
| 10 |
Hereditary gastrointestinal cancers: why genetic counseling matters
|
Taieb, J.
|
|
|
30 |
10 |
p. 1535-1536
|
article
|
| 11 |
How liquid biopsies can change clinical practice in oncology
|
Siravegna, G.
|
|
|
30 |
10 |
p. 1580-1590
|
article
|
| 12 |
Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance
|
Solomon, B.
|
|
|
30 |
10 |
p. 1638-1646
|
article
|
| 13 |
Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China
|
Ji, M.F.
|
|
|
30 |
10 |
p. 1630-1637
|
article
|
| 14 |
Is the tumour microenvironment a critical prognostic factor in early-stage colorectal cancer?
|
Nyamundanda, G.
|
|
|
30 |
10 |
p. 1538-1540
|
article
|
| 15 |
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
|
Kurzrock, R.
|
|
|
30 |
10 |
p. 1647-1652
|
article
|
| 16 |
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
|
Weiss, J.M.
|
|
|
30 |
10 |
p. 1613-1621
|
article
|
| 17 |
Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?
|
Belderbos, B.P.S.
|
|
|
30 |
10 |
p. 1591-1600
|
article
|
| 18 |
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer
|
Seiwert, T.Y.
|
|
|
30 |
10 |
p. 1673
|
article
|
| 19 |
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
|
Aguilar, E.J.
|
|
|
30 |
10 |
p. 1653-1659
|
article
|
| 20 |
Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath
|
de Vries, R.
|
|
|
30 |
10 |
p. 1660-1666
|
article
|
| 21 |
Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy
|
Pastorino, U.
|
|
|
30 |
10 |
p. 1672
|
article
|
| 22 |
Quantitative lymph node burden as a ‘very-high-risk’ factor identifying head and neck cancer patients benefiting from postoperative chemoradiation
|
Zumsteg, Z.S.
|
|
|
30 |
10 |
p. 1669
|
article
|
| 23 |
Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
|
Dienstmann, R.
|
|
|
30 |
10 |
p. 1622-1629
|
article
|
| 24 |
St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patients’ overtreatment and breaking the bank?
|
Arnedos, M.
|
|
|
30 |
10 |
p. 1533-1535
|
article
|
| 25 |
Table of Contents
|
|
|
|
30 |
10 |
p. iv-v
|
article
|
| 26 |
The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
|
Elkrief, A.
|
|
|
30 |
10 |
p. 1572-1579
|
article
|
| 27 |
When is off-label off-road?
|
de Vries, E.G.E.
|
|
|
30 |
10 |
p. 1536-1538
|
article
|
Journal description